Drug – bio-affecting and body treating compositions – Immunoglobulin – antiserum – antibody – or antibody fragment,...
Reexamination Certificate
2005-01-18
2005-01-18
Canella, Karen A. (Department: 1642)
Drug, bio-affecting and body treating compositions
Immunoglobulin, antiserum, antibody, or antibody fragment,...
C424S133100, C424S134100, C424S135100, C424S141100, C424S144100, C424S153100, C424S155100, C424S173100, C424S174100, C424S178100, C424S181100, C424S183100, C530S387100, C530S387300, C530S388100, C530S388220, C530S388730, C530S388800, C530S388850, C530S391100, C530S391700
Reexamination Certificate
active
06843989
ABSTRACT:
The present invention relates to methods and compositions for the prevention and treatment of cancer, inflammatory diseases and disorders or deficiencies of the immune system. The methods of the invention comprise administering a CD40 binding protein that potentiates the binding of CD40 to CD40 ligand.
REFERENCES:
patent: 5182368 (1993-01-01), Ledbetter et al.
patent: 5354847 (1994-10-01), Liu et al.
patent: 5530101 (1996-06-01), Queen et al.
patent: 5540926 (1996-07-01), Aruffo et al.
patent: 5597569 (1997-01-01), Siegall et al.
patent: 5674492 (1997-10-01), Armitage et al.
patent: 5677165 (1997-10-01), de Boer et al.
patent: 5872215 (1999-02-01), Osbourne et al.
patent: 5874082 (1999-02-01), DeBoer
patent: 5985847 (1999-11-01), Carson et al.
patent: 6056959 (2000-05-01), de Boer et al.
patent: WO 9618413 (1996-06-01), None
patent: WO 9833810 (1998-08-01), None
Apostolopoulos et al, “Muc1 cross-reactive Gal alpha(1,3)Gal antibodies in humans switch immune response from cellular to humoral”, Nature Medicine, 1998, vol. 4, pp. 315-320.*
Henriquez et al, “Differential response to CD40 ligation”, Journal of Immunology, 1999, vol. 162, pp. 3298-3307.*
Buhmann et al, “CD40-activated B-cell chronic lymphocytic leukemia cells for tumor immunotherapy”, Blood, 1999, vol. 93, pp. 1992-2002.*
Andersen et al, “Soluble CD40 ligand induces cell cycle progression in primary mantle cell lymphoma” Blood, 1999, vol. 94, No. 10, Suppl. 1, p. 630a.*
Vonderheide et al, “CD40 ligation of solid tumors does not induce the surface phenotype characteristic of professional antigen presenting cells”, Proceed Amer Assoc Cancer Research, 1999, vol. 40, p. 472.*
Becker et al, “Tumor escape mechanisms from immunosurvillance”, International Immunology, 1993, vol. 5, pp. 1501-1508.*
Hiraki et al, “Loss of HLA haplotype in lung cancer cell lines:Implications for immunosurveillance of altered HLA Class I/II phenotypes in cancer”, Clinical Cancer Research, 1999, vol. 5, pp. 933-936.*
Ada, G., “The coming of age of immunotherapy”, Immunology and Cell biology, 1999, vol. 77, pp. 180-185.*
Gura, T. , “Systems for identifying new drugs are often faulty”, Science, 1997, vol. 278, pp. 1041-1042.*
Matsui, et al, “A model for CD+8 CTL tumor immunosurveillance and regulation of tumor escape by CD+4 cells”, J. Immunology, 1999, vol. 163, pp. 184-193.*
Funakoshi et al (Blood, 1994, vol. 83, pp. 2787-2794).*
Unkun et al (Blood, 1990, vol. 76, pp. 2449-2456).*
the abstract of Kawaguchi et al (Proc Annu Meet Am Assoc Cancer Res, 1997, vol. 38, p. A2319.*
Schlom (In: Molecular foundations of Oncology, Sameule Broader, Ed, 1991, pp. 95-134).*
the abstract of Bender et al (Human antibodies and Hybridomas, 1993, vol. 4, pp. 74-79).*
Costello et al (Archivum Immunologiae et Therapiae Experimentalis, Feb. 1999, vol. 47, pp. 83-88).*
Buhmann et al (Blood, 1999, vol. 93, pp. 1992-2002).*
Caux et al (journal of Experimental Medicine, 1994, vol. 180, pp. 1263-1272).*
Cella et al (Journal of Experimental Medicine, 1996, vol. 184, pp. 747-752).*
Francisco et al, Journal of Biological Chemistry, 1997, vol. 272, pp. 24165-24169.*
Paulie et al, Journal of Immunology, 1989, vol. 142, pp. 590-595.*
Melief et al (U. S. Application 2003/0022860.*
the abstract of Schultze et al (Blood, 1996, vol. 88, No. 10, suppl. 1, part 1-2, p. 162A.*
the abstract of Sotomayor et al (Blood, 1998, vol. 92, No. 10, suppl. 1, part 1-2, p. 541A).*
Schultze (Haematology and Blood Transfusion, 1998, vol. 39, pp. 716-731).*
Ghetie et al., 1990, “Disseminated or Localized Growth of a Human B-Cell Tumor (Daudi) in Scid Mice”, Int. J. Cancer 45:481-485.
Kawata et al., 1994, “Establishment of New SCID and Nude Mouse Models of Human B-Leukemia/Lymphoma and Effective Therapy of the Tumors with Immunotoxin and Monoclonal Antibody: Marked Difference between the SCID and Nude Mouse Models in the Antitumor Efficacy of Monoclonal Antibody”, Cancer Research 54: 2688-2694.
Cattan and Douglas, 1994, “The C.B. 17 Scid Mouse Strain as a Model for Human Disseminated Leukaemia and Myeloma in Vivo”, Leukemia Research 18:513-522.
Buchsbaum et al., 1992, “Improved Delivery of Radiolabeled Anti-B1 Monoclonal Antibody to Raji Lymphoma Xenografts by Predosing with Unlabeled Anti-B1 Monoclonal Antibody”, Cancer Research 52:637-642.
Kaminsky et al., 2001, “Pivotal Study of Iodine 1 131 Tositumomab for Chemotherapy-Refractory Low-Grade of Transformed Low-Grade B-Cell Non-Hodgkin's Lymphomas”, J. of Clinical Oncology 19:3918-3928.
Ostrowski et al., 2001, “Inhibition of Angiogenesis in the Treatment of Tumors”, Archivum Immunologiae et Therapiae Experimentalis 49:27-31.
Pound et al., 1998, “Minimal cross-linking and epitope requirements for CD40-dependent suppression of apoptosis contrast with those for promotion of the cell cycle and homotypic adhesions in human B cells”, Int'l Immunology 11:11-20.
Hirano et al., 1999, “Inhibition of human breast carcinoma growth by a soluble recombinant human CD40 ligand”, Blood 93(9):2999-3007.
Accession No. W78434, 1998, Antibody light chain directed to HER3 clone 18.
Accession No. Y06716, 1999, Antibody 12B5 single chain Fv (scFv) fragment.
www.ncbi.nlm.nih.gov (National Center for Biotechnology Information) GenBank Protein Accession No. S69899, 1997, Ig heavy chain V region (clone RFTS7H), rheumatoid factor—human.
www.ncbi.nlm.nih.gov (National Center for Biotechnology Information) GenBank Protein Accession No. S67941, 1997, Ig heavy chain variable region, subgroup I (clone MH52)—human (fragment).
www.ncbi.nlm.nih.gov (National Center for Biotechnology Information) GenBank Protein Accession No. C29380, 1988, Ig kappa chain precursor V region (BC-1004)—mouse (fragment).
Alessandrini and Desiderio, “Coordination of Immunoglobulin DJHTranscription and D-to-JHRearrangement by Promoter-Enhancer Approximation,” Molecular Biology, 1991, 11(4):2096-2107.
Armitage et al., “Distinct patterns of inhibition by CD40 mAb of the CD40 ligand-CD40 interaction,” inLeukocyte Typing V,Schlossman et al. (Eds.) 1995; 1: 551-552.
Bjorck and Paulie, “CD40 Antibodies defining distinct epitopes display qualitative differences in their induction of B-cell differentiation,” Immunology, 1996, 97, 291-295.
Bjorck et al., “Antibodies to distinct epitopes on the CD40 molecule co-operate in stimulation and can be used for the detection of soluble CD40,” 1994, 83, 430-437.
Bubenik J et al., “Monoclonal antibodies against human urinary bladder carcinomas: selectivity and utilization for gamma scintigraphy,” Eur J Cancer Clin Oncol. Jun. 1985;21(6):701-10.
Challa A et al., “Epitope-dependent synergism and antagonism between CD40 antibodies and soluble CD40 ligand for the regulation of CD23 expression and IgE synthesis in human B cells,” Allergy. Jun. 1999;54(6):576-83.
Chen et al., “Nucleotide and translated amino acid sequences of cDNA coding for the variable regions of the light and heavy chains of mouse hybridoma antibodies to blood group A and B substances,” Journal of Biological Chemistry, 1987, 282(28):13579-13583.
Clark EA and Ledbetter JA, “Activation of human B cells mediated through two distinct cell surface differentiation antigens, Bp35 and Bp50,” Proc Natl Acad Sci U S A. Jun. 1996;83(12):4494-8.
De Paoli P, “High CD40 membrane expression in AIDS-related lymphoma B cell lines is associated with the CD45RA+, CD45RO+, CD95+ phenotype and high levels of its soluble form in culture supermatants,” Cytometry. Feb. 15, 1997;30(1):33-8.
Fanslow et al., “CD40 mAb M2 and M3 inhibit CD40 ligand binding and function,” inLeukocyte Typing IV,Schlossman et al. (Eds.) 1994; 1: 555-556.
Francisco JA et al., “Construction, expression, and characterization of BD1-G28-5 sFv, a single-c
Fell, Jr. Henry Perry
Francisco Joseph A.
Siegall Clay B.
Wahl Alan F.
Canella Karen A.
Conforti Vita G.
Day Jones
Seattle Genetics Inc.
LandOfFree
Methods for the treatment and prevention of cancer using... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods for the treatment and prevention of cancer using..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods for the treatment and prevention of cancer using... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3417721